Trials / Completed
CompletedNCT05288491
A Study of Chinese Adults With Lymphoma
Concordance Study of CD30 Expression Detected by Multiple Immunohistochemistry Assays and VENTANA CD30 Assay in Chinese Lymphoma Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 934 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to improve methods of clinical testing and therapy for lymphoma participants. This study will involve collecting information about participants from past medical records.
Detailed description
This is an observational, non-interventional, retrospective study to evaluate staining and interpretation concordance of CD30 expression detected by 9 immunohistochemistry (IHC) assays and VENTANA CD30 IHC assay in Chinese lymphoma participants. This study will enroll approximately 1000 participants. The data will be collected via chart review in the electronic case report forms (eCRFs). All the participants will be assigned to a single observational cohort: • Participants With Malignant Lymphoma This multi-center trial will be conducted in China. The overall duration of the study will be approximately 21 months.
Conditions
Timeline
- Start date
- 2022-10-31
- Primary completion
- 2024-06-20
- Completion
- 2024-06-20
- First posted
- 2022-03-21
- Last updated
- 2024-08-12
Locations
19 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05288491. Inclusion in this directory is not an endorsement.